Clinical Trial Update: Study of GNX102 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of GNX102 in patients with advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor
• Unresectable Solid Tumor

Drugs mentioned

• GNX102 (GNX102)

Snippet

Sponsor: GlycoNex, Inc. | Conditions: Solid Tumor, Metastatic Cancer | Phase 1 | Status: TERMINATED